Intratumoral inflammatory infiltrate can predict prognostic and evolution into malignant breast cancer?

The objective was to evaluate the intratumoral inflammatory infiltrate in in situ and invasive breast cancer. Analysis of 77 patients: 28 with non-neoplastic lesions, 17 with in situ, and 32 with invasive carcinomas for CD 3, 4, 7, 8, 20, 25, 57, and 68. The authors observed weak positive immunostaining significantly higher in non-neoplastic lesions, and strong in malignant neoplasia. There were no cases of weak CD 8 expression in high histological grade in situ and invasive group. There was no strong CD 20 expression in low grade invasive carcinomas, nor weak in high grade in situ group. The authors did not observe strong CD 57 immunoreactivity in situ group with low or high grade. CD 7 strong immunoexpression was associated with an absence of metastases in lymph nodes. Differences in inflammatory intratumoral cell migration exist between non-neoplastic breast lesions and carcinomas, the histological grade of the tumor, and in the absence of axillary metastases.

Breast cancer; Lymphocytes; Immune system; Immune response; Immunohistochemistry.

[1] Iorio M.V., Casalini P., Tagliabue E., Ménard S., Croce C.M.: “MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer”. Eur. J. Cancer, 2008, 18, 2753.

[2] Mohammed R.A., Ellis I.O., Lee A.H., Martin S.G.: “Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms”. Histopathology, 2009, 1, 1.

[3] Caleffi M., Ribeiro R.A., Duarte Filho D.L., Ashton-Prolla P., Bedin A.J. Jr., Skonieski G.P., et al.: “A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort)”. BMC Public Health, 2009, 9, 83.

[4] Honeth G., Bendahl P.O., Ringnér M., Saal L.H., Gruvberger-Saal S.K., Lövgren K., et al.: “The CD44positive/CD24- phenotype is enriched in basal-like breast tumors”. Breast Cancer Res., 2008, 3, 1.

[5] Loose D., Van de Wiele C.: “The immune system and cancer”. Cancer Biother. Radiopharm., 2009, 3, 369.

[6] Estrela-Lima A., Araújo M.S., Costa-Neto J.M., Teixeira-Carvalho A., Barrouin-Melo S.M., Cardoso S.V., et al.: “Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates”. BMC Cancer, 2010, 10, 256.

[7] Cheever M.A., Disis M.L.: “Imunologia e Imunoterapia”. In: Harris J., Lippman M., Morrow M., Osborne C.K. (eds). Doenças da Mama 2nd ed. Rio de Janeiro: Medsi Editora Médica e Científica Ltda., 2009, 971.

[8] Sotiriou C., Equeter C., El Ouriaghli F., Haibe-Kains B., Durbecq V., Larsimont D., et al.: “Correlation of gene expression analysis of tumor-infiltrating CD4positive cells with immune function and survival according to different breast cancer (BC) molecular subtypes”. JCO, 2008, 26, 110.

[9] Ben-Hur H., Cohen O., Schneider D., Gurevich P., Halperin R., Bala U., et al.: “The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study”. Anticancer Res., 2002, 22, 1231.

[10] Kim S., Lee A., Lim W., Park S., Cho M.S., Koo H., et al.: “Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer”. J. Breast Cancer, 2014, 1, 8.

[11] Liu F., Lang R., Zhao J., Zhang X., Pringle G.A., Fan Y., et al.: “CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes”. Breast Cancer Res. Treat., 2011, 2, 645.

[12] Loi S., Dushyanthen S., Beavis P.A., Salgado R., Denkert C., Savas P., et al.: “RAS/MAPK Activation is associated with reduced tumorinfiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors”. Clin. Cancer Res., 2016, 22, 1499.

[13] Elston C.W., Ellis I.O.: “Assessment of histological grade”. 3rd ed. Edinburg, Alemanha: Churchil Livingstone, 1999, 365.

[14] Edge S., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti, A.: “Cancer Staging Manual”. 7th ed. New York, USA: Springer 2010, 347.

[15] Georgiannos S.N., Renaut A., Goode A.W., Sheaff M.: “The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators”. Surg., 2003, 5, 827.

[16] Varella P.P.V., Neves Forte W.C.: “Citokines: a review”. Rev. Bras. Alerg. Imunopatol., 2001, 24, 146.

[17] Taylor C.R., Cote R.J.: “Immunomicroscopy. A diagnostic tool for the surgical pathologist”. 3rd ed. Philadelphia, USA: Sauders Elsevier 2006, 103.

[18] Yamagami W., Susumu N., Tanaka H., Hirasawa A., Banno K., Suzuki N., et al.: “Immunofluorescence-detected infiltration of CD4 positive FOXP3 positive regulatory T cells is relevant to the prognosis of patients with endometrial cancer”. Int. J. Gynecol. Cancer, 2011, 9, 1628.

[19] Carvalho M.I., Pires I., Prada J., Queiroga F.L.: “A role for T-lymphocytes in human breast cancer and in canine mammary tumors”. Biomed. Res. Int., 2014, 2, 201.

[20] Hiura T., Kagamu H., Miura S., Ishida A., Tanaka H., Tanaka J., et al.: “Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression”. J. Immunol., 2005, 8, 5058.

[21] Kosmaczewska A., Ciszak L., Potoczek S., Frydecka I.: “The significance of Treg cells in defective tumor immunity”. Arch. Immunol. Ther. Exp. (Warsz.), 2008, 3, 181.

[22] Yu P., Fu Y.X.: “Tumor-infiltrating T lymphocytes: friends or foes?” Lab. Invest., 2006, 3, 231.

[23] Chretien A.S., Le Roy A., Vey N., Prebet T., Blaise D., Fauriat C., et al.: “Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological atrategies aiming at restoring NK-mediated anti-tumor activity”. Front. Immunol., 2014, 5, 122.

[24] Fridman W.H., Pagès F., Sautès-Fridman C., Galon J.: “The immune contexture in human tumours: impact on clinical outcome”. Nat. Rev. Cancer, 2012, 4, 298.

[25] Platonova S., Cherfils-Vicini J., Damotte D., Crozet L., Vieillard V., Validire P., et al.: “Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma”. Cancer Res., 2011, 16, 5412.

[26] Mantovani A.: “B cells and macrophages in cancer: yin and yang”. Nat. Med., 2011, 3, 285.

[27] DiLillo D.J., Yanaba K., Tedder T.F.: “B cells are required for optimal CD4positive and CD8positive T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice”. J. Immunol., 2010, 7, 4006.

[28] Mantovani A., Allavena.P, Sica A., Balkwill F.: “Cancer-related inflammation”. Nature, 2008, 7203, 436.

[29] Menegaz R.A., Michelin M.A., Etchebehere R.M., Fernandes P.C., Murta E.F.: “Peri- and intratumoral T and B lymphocytic infiltration in breast cancer”. Eur. J. Gynaecol. Oncol., 2008, 4, 321.

[30] Silva C.S., Michelin M.A., Etchebehere R.M., Adad S.J, Murta E.F.: “Local lymphocytes and nitric oxide synthase in the uterine cervical stroma of patients with grade III cervical intraepithelial neoplasia”. Clinics, 2010, 6, 575.